8-K: Alphatec Holdings Reports Strong Q3 2024 Results, Boosts Full-Year Outlook

Alphatec Holdings, Inc. announced robust third-quarter 2024 financial results, highlighted by a 30% surgical revenue growth and a 27% total revenue increase, leading to an improved full-year guidance.

Summary

• Alphatec Holdings, Inc. reported a 30% increase in surgical revenue and a 27% increase in total revenue for the third quarter of 2024.
• Total revenue reached $151 million, with a GAAP gross margin of 68% and a non-GAAP gross margin of 69%.
• The company's GAAP operating expenses were $136 million, while non-GAAP operating expenses were $114 million.
• ATEC reported a GAAP net loss of $40 million but achieved an adjusted EBITDA of $7.4 million, representing a 5% margin.
• The company ended the quarter with a cash balance of $81 million.
• Procedural volume grew by 20%, driven by the continued momentum of PTP and LTP systems.
• New surgeon adoption increased by 19%, indicating future growth potential.
• ATEC expanded its U.S. footprint, resulting in over 200 surgeon training engagements.
• Free cash use was reduced to $21 million as the accelerated investment phase nears completion.
• The company has increased its full-year 2024 revenue guidance to $605 million, up from $602 million, with surgical revenue expected to be $540 million and EOS revenue at $65 million.
• Non-GAAP adjusted EBITDA for the full year is now projected to be approximately $27 million, compared to the previous estimate of $25.5 million.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the significant revenue growth, increased guidance, and successful expansion of the term loan facility. While there is a GAAP net loss, the adjusted EBITDA and future outlook are promising, indicating a positive trajectory for the company.

Positives

• The company experienced strong surgical revenue growth of 30% and total revenue growth of 27%.
• ATEC achieved a 19% growth in new surgeon adoption, a key indicator of future growth.
• The company successfully reduced free cash use to $21 million.
• The expansion of the term loan facility provides enhanced balance sheet flexibility.
• The company has increased its full-year revenue and profitability guidance.

Negatives

• The company reported a GAAP net loss of $40 million for the quarter.
• GAAP operating expenses were $136 million, which is higher than non-GAAP operating expenses of $114 million.

Risks

• The company's future performance is subject to risks and uncertainties, including the success of new products, ability to execute strategic plans, and market acceptance of products.
• There are uncertainties regarding the ability to obtain regulatory clearances and approvals, and the continuation of favorable third-party reimbursement.
• The company faces risks related to product liability, litigation, patent infringement claims, and the ability to meet financial obligations.

Future Outlook

The company expects total revenue to grow 25% to $605 million for the full year 2024, with non-GAAP adjusted EBITDA of approximately $27 million.

Management Comments

• Pat Miles, Chairman and CEO, stated that ATEC's commitment is to enhance spine care through innovation.
• He also noted the importance of converting growth to expand profitability and the company's active execution of internal initiatives to impact cash flow.
• Pedro Gonzalez de Cosio, Co-Founder, Principal and CEO of Pharmakon Advisors, expressed excitement to partner with ATEC in support of its mission to improve spine care.

Industry Context

The announcement reflects a positive trend in the medical device industry, particularly in the spine surgery sector, where innovation and growth are key drivers. ATEC's performance indicates a strong competitive position and potential for continued expansion.

Comparison to Industry Standards

• ATEC's 30% surgical revenue growth significantly exceeds the average growth rate in the spine surgery market, which is typically in the single to low double-digit percentages.
• The company's 19% growth in new surgeon adoption is a strong indicator of future market share gains, as it suggests increasing preference for ATEC's products among surgeons.
• While the company reported a GAAP net loss, the positive adjusted EBITDA and improved full-year guidance suggest a path towards profitability, which is a key focus for investors in the medical device sector.
• The $50 million expansion of the term loan facility provides ATEC with additional financial flexibility, which is crucial for companies in the medical device industry that require significant capital for research, development, and commercialization.
• Compared to competitors like Medtronic, Johnson & Johnson, and Stryker, ATEC's growth rate is notably higher, indicating a strong market position and potential for continued expansion.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and improved profitability outlook.
• Employees may benefit from the company's growth and expansion.
• Customers (surgeons) will have access to innovative solutions and training programs.
• Creditors will benefit from the company's enhanced financial stability and increased cash flow.

Next Steps

• The company will continue to execute internal initiatives to impact cash flow.
• The company will focus on converting growth to expand profitability.
• The company will continue to expand its U.S. footprint and drive surgeon training engagements.

Key Dates

Keywords

spine surgery, surgical revenue, financial results, revenue growth, EBITDA, term loan, medical devices, surgeon adoption, procedural volume, financial guidance